Never Run Out Of Buyers To Sell To.

ABSCINT specializes in advanced in vivo imaging diagnostics, focusing on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting. ABSCINT’s primary product is a specific anti-HER2 PET tracer, which enables comprehensive whole-body imaging for evaluating disease heterogeneity in HER2-low and HER2-positive breast cancer. This non-invasive technology offers rapid imaging results within 90 minutes, with minimal radiation exposure. This innovation also opens the door to HER2 reclassification via image-guided biopsies, enhancing diagnostic accuracy, patient…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.